The state-of-the-art multipurpose multi-product facility is proposed to be set up in the Pharmaceutical Industrial Park, Seri Iskandar, Ipoh, Perak State Malaysia. The location offers several advantages like single window clearance of all regulatory issues, tax holidays, common effluent treatment, uninterrupted power supply, wonderful landscape, housing colony, school and other related facilities.
Project will generate high revenues with proposed overall production of 710 kg of APIs. Higher production is possible within the same facility through company’s in-house R & D program and thus, possibility of higher revenues is evident.
Approval from Government of Malaysia for 100% EOU status with associated tax exemptions will be possible.
Unique high value biopharmaceutical products and fewer competitions.
Proven commercial Technologies with non-infringing processes from Saamya Biotech (India) Ltd., the main promoter of the company
100% buy back arrangement with M/s Arch Pharmalabs Ltd., Mumbai, India.
Higher returns are envisaged on capital employed
Minimum gestation period.
Company will be debt free after VII yrs and considers dividend to shareholders from the 2nd yr of operation.
The company is backed by renowned Scientists and Technocrats in the field of biotechnology.